Low prevalence and disease severity of COVID-19 in post-liver transplant recipients-A single centre experience.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
08 2020
Historique:
received: 06 05 2020
revised: 26 05 2020
accepted: 27 05 2020
pubmed: 30 5 2020
medline: 18 11 2020
entrez: 30 5 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is driving a present day global pandemic. Immunosuppressed patients are regarded as a high-risk cohort. The following is a short report on COVID-19 in liver transplant recipients (n = 5) from a high volume UK liver transplant unit with a large follow-up cohort (n = 4500). Based on this limited data, liver transplant recipients appear to have a low incidence of COVID-19, with less severe symptoms than expected, when compared with the general population and other solid organ recipients. This possibly could be related to self-isolation adherence and/or the 'ideal' level of immunosuppression that favourably modulates the immune response to COVID-19.

Identifiants

pubmed: 32471013
doi: 10.1111/liv.14552
pmc: PMC7300707
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1972-1976

Informations de copyright

© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.

Références

Am J Transplant. 2020 Jul;20(7):1902-1906
pubmed: 32324331
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Viruses. 2013 May 22;5(5):1250-60
pubmed: 23698397
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366
Am J Transplant. 2020 Jul;20(7):1875-1878
pubmed: 32198834
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Transplantation. 2020 Oct;104(10):1974-1983
pubmed: 32243281
Liver Int. 2020 Aug;40(8):1972-1976
pubmed: 32471013
Metabolism. 2020 Jul;108:154244
pubmed: 32320741
Age Ageing. 2020 Jul 1;49(4):523-524
pubmed: 32315386
Virus Res. 2012 Apr;165(1):112-7
pubmed: 22349148
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134

Auteurs

Anita Verma (A)

Institute of Liver Studies, King's College Hospital, London, UK.

Shirin Elizabeth Khorsandi (SE)

Institute of Liver Studies, King's College Hospital, London, UK.

Annalisa Dolcet (A)

Institute of Liver Studies, King's College Hospital, London, UK.

Andreas Prachalias (A)

Institute of Liver Studies, King's College Hospital, London, UK.

Abid Suddle (A)

Institute of Liver Studies, King's College Hospital, London, UK.

Nigel Heaton (N)

Institute of Liver Studies, King's College Hospital, London, UK.

Wayel Jassem (W)

Institute of Liver Studies, King's College Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH